Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Innovent Biologics
Biotech
Innovent links IL-2 fusion protein to responses in small study
Innovent's bispecific immuno-oncology candidate IBI363 has been linked to a 100% response rate in a small cohort of Chinese lung cancer patients.
Nick Paul Taylor
Jun 14, 2024 10:00am
Innovent's Tepezza rival closer to China nod after phase 3 win
Feb 20, 2024 8:38am
Next-gen Lilly obesity drug secures first phase 3 win for Innovent
Jan 9, 2024 5:29am
Innovent’s rival to AbbVie, J&J psoriasis drugs clears phase 2
Aug 10, 2022 6:50am
Sanofi pens 'pioneering' cancer drug deal with China's Innovent
Aug 4, 2022 3:07pm
Phase 3 hits tee Innovent up to rival Amgen and Sanofi in PCSK9
Feb 17, 2022 9:40am
